Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 7/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098692 | 0.77 | MAPT (0.41) | MAPTLMNATP53POLBPABPC1 | |
| SCHEMBL17059804 | 0.76 | MAPK7 (0.54) | MAPTLMNAHPGDALDH1A1 | |
| SCHEMBL14288794 | 0.76 | MAOA (0.64) | MAPTLMNATP53POLBPABPC1 | |
| SCHEMBL19826819 | 0.74 | MAPT (0.56) | MAPTLMNATP53POLBPABPC1 | |
| SCHEMBL17059742 | 0.74 | MAPK7 (0.57) | HPGDALDH1A1 | |
| SCHEMBL17059740 | 0.74 | MAPK7 (0.42) | POLBHPGDALDH1A1 | |
| SCHEMBL19816451 | 0.73 | NOX1 (0.68) | MAPTLMNATP53POLBPABPC1 | |
| SCHEMBL17059949 | 0.73 | MAPK7 (0.70) | MAPTLMNATP53POLBHPGD | |
| SCHEMBL17059746 | 0.72 | L3MBTL1 (0.58) | MAPTTP53POLBHPGDRXFP1 | |
| SCHEMBL18369821 | 0.72 | CA9 (0.41) | LMNAPABPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | ACTIVX BIOSCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2015129927-A1 | HETEROCYCLIC COMPOUNDS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008888-A1 | HETEROCYCLIC COMPOUNDS | BET1, EP300, RBBP5 | MAPT 2379/4885LMNA 1597/4885TP53 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.